Literature DB >> 30178516

Should sodium-glucose co-transporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes?

Kamlesh Khunti1, Samuel Seidu1, Melanie J Davies1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30178516     DOI: 10.1111/dom.13518

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


× No keyword cloud information.
  2 in total

Review 1.  Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

Authors:  Brendon L Neuen; Meg J Jardine; Vlado Perkovic
Journal:  Nephrol Dial Transplant       Date:  2020-01-01       Impact factor: 5.992

2.  Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.

Authors:  Brendon L Neuen; Clare Arnott; Vlado Perkovic; Gemma Figtree; Dick de Zeeuw; Greg Fulcher; Min Jun; Meg J Jardine; Sophia Zoungas; Carol Pollock; Kenneth W Mahaffey; Bruce Neal; Hiddo J L Heerspink
Journal:  Diabetes Obes Metab       Date:  2020-10-29       Impact factor: 6.577

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.